Researchers from the University of Arkansas have reported that the addition of Thalomid (thalidomide) to autologous stem cell transplantation does not improve survival for patients with newly diagnosed multiple myeloma. The details of this study appeared in an article recently published in the March 9, 2006 issue of the New England Journal of Medicine.